Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML

Ming Hong; Han Zhu; Qian Sun; Yu Zhu; Yi Miao; Hui Yang; Hai-Rong Qiu; Jian-Yong Li; Si-Xuan Qian

doi:doi:10.18632/aging.102973

← Back

Research Paper Volume 12, Issue 7 pp 5792—5811

Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML

Figure 2. Change in TP53^mut (A), FLT3^mut (B), and NPM1^mut (C) VAF in responders and non-responders to D-CAG with paired samples at diagnosis and after 1 cycle.